KMT2A and leukemia: A second trial (www.clinicaltrials.gov; NCT01684150), performed on 51 adult MLL-r leukemia patients treated intravenously with Pinometostat for 28-day cycles at different doses, produced a complete remission in two patients, although the overall efficacy as a single agent was modest suggesting the need of further clinical investigations of combination approaches for leukemia treatment (Stein et al., 2018).